1052 related articles for article (PubMed ID: 19389019)
21. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial.
Dowson C; Sahai A; Watkins J; Dasgupta P; Khan MS
Int J Clin Pract; 2011 Jun; 65(6):698-704. PubMed ID: 21564444
[TBL] [Abstract][Full Text] [Related]
22. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection.
Lucioni A; Rapp DE; Gong EM; Fedunok P; Bales GT
Can J Urol; 2006 Oct; 13(5):3291-5. PubMed ID: 17076955
[TBL] [Abstract][Full Text] [Related]
23. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
24. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
[TBL] [Abstract][Full Text] [Related]
25. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
Kuo HC
Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.
Schulte-Baukloh H; Schobert J; Stolze T; Stürzebecher B; Weiss C; Knispel HH
Neurourol Urodyn; 2006; 25(2):110-5. PubMed ID: 16470519
[TBL] [Abstract][Full Text] [Related]
27. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction.
Schulte-Baukloh H; Weiss C; Stolze T; Herholz J; Stürzebecher B; Miller K; Knispel HH
Eur Urol; 2005 Dec; 48(6):984-90; discussion 990. PubMed ID: 16126328
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
29. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.
Rajkumar GN; Small DR; Mustafa AW; Conn G
BJU Int; 2005 Oct; 96(6):848-52. PubMed ID: 16153215
[TBL] [Abstract][Full Text] [Related]
30. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?
Kuo HC
Urology; 2006 Nov; 68(5):993-7; discussion 997-8. PubMed ID: 17113890
[TBL] [Abstract][Full Text] [Related]
31. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment.
Roosen A; Datta SN; Chowdhury RA; Patel PM; Kalsi V; Elneil S; Dasgupta P; Kessler TM; Khan S; Panicker J; Fry CH; Brandner S; Fowler CJ; Apostolidis A
Eur Urol; 2009 Jun; 55(6):1440-8. PubMed ID: 19054608
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
[TBL] [Abstract][Full Text] [Related]
33. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
[TBL] [Abstract][Full Text] [Related]
34. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
Bach P; Wormland RT; Möhring C; Goepel M
Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
[TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
Schurch B; Denys P; Kozma CM; Reese PR; Slaton T; Barron RL
Eur Urol; 2007 Sep; 52(3):850-8. PubMed ID: 17467889
[TBL] [Abstract][Full Text] [Related]
36. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
37. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
Naumann M; Lowe NJ; Kumar CR; Hamm H;
Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
[TBL] [Abstract][Full Text] [Related]
38. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction.
Schulte-Baukloh H; Weiss C; Stolze T; Stürzebecher B; Knispel HH
Urology; 2005 Jul; 66(1):82-7. PubMed ID: 15992872
[TBL] [Abstract][Full Text] [Related]
39. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
Del Popolo G; Filocamo MT; Li Marzi V; Macchiarella A; Cecconi F; Lombardi G; Nicita G
Eur Urol; 2008 May; 53(5):1013-19. PubMed ID: 17950989
[TBL] [Abstract][Full Text] [Related]
40. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
